Theravance Biopharma, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | — | $293.9M | $169.9M |
| Jun 2017 | — | $241.1M | $139.6M |
| Sep 2017 | — | $184.1M | $91.3M |
| Dec 2017 | $223.7M | $115.2M | $89.0M |
| Mar 2018 | — | $63.4M | $125.8M |
| Jun 2018 | — | $34.4M | $103.9M |
| Sep 2018 | — | $-13.4M | $101.2M |
| Dec 2018 | $454.4M | $-51.6M | $378.0M |
| Mar 2019 | — | $-113.3M | $223.2M |
| Jun 2019 | — | $-137.2M | $178.3M |
| Sep 2019 | — | $-182.8M | $102.4M |
| Dec 2019 | $455.0M | $-223.8M | $58.1M |
| Mar 2020 | — | $-157.9M | $332.8M |
| Jun 2020 | — | $-202.3M | $104.7M |
| Sep 2020 | — | $-261.5M | $93.3M |
| Dec 2020 | $619.2M | $-303.8M | $81.5M |
| Mar 2021 | $614.1M | $-373.2M | $114.0M |
| Jun 2021 | $609.5M | $-300.4M | $204.9M |
| Sep 2021 | $615.9M | $-323.6M | $121.4M |
| Dec 2021 | $616.3M | $-338.6M | $90.0M |
| Mar 2022 | $621.5M | $-351.5M | $94.4M |
| Jun 2022 | $624.7M | $-349.8M | $87.3M |
| Sep 2022 | — | $480.6M | $418.5M |
| Dec 2022 | — | $441.8M | $298.2M |
| Mar 2023 | — | $370.6M | $187.7M |
| Jun 2023 | — | $280.2M | $105.6M |
| Sep 2023 | — | $246.1M | $71.7M |
| Dec 2023 | $0 | $213.0M | $39.5M |
| Mar 2024 | — | $204.9M | $53.8M |
| Jun 2024 | — | $193.7M | $46.3M |
| Sep 2024 | — | $185.7M | $23.4M |
| Dec 2024 | — | $175.5M | $37.8M |
| Mar 2025 | — | $166.0M | $110.6M |
| Jun 2025 | — | $224.8M | $281.9M |
| Sep 2025 | — | $232.7M | $174.8M |
| Dec 2025 | — | $296.7M | $167.8M |
| Mar 2026 | — | $290.6M | $288.1M |
| Jun 2026 | — | $289.7M | $219.8M |